BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34854030)

  • 1. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
    Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
    Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
    Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
    J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
    Zhang Y; Ascaso C; Herreros A; Sánchez J; Sabater S; Pino MD; Li Y; Gómez G; Torné A; Biete A; Rovirosa Á
    Rep Pract Oncol Radiother; 2020; 25(2):227-232. PubMed ID: 32042274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
    Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
    Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
    Zhang Y; Noorian F; Abellana R; Rochera J; Herreros A; Antelo G; Lancellotta V; Tagliaferri L; Han Q; Torne A; Rovirosa A
    Clin Transl Oncol; 2023 Jun; 25(6):1748-1755. PubMed ID: 36752959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy.
    Small W; Erickson B; Kwakwa F
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1502-7. PubMed ID: 16109462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
    Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
    Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
    Zhang Y; Rovirosa A; Ascaso C; Herreros A; Torne A; Li Y; Biete A; Sánchez J
    Brachytherapy; 2020; 19(1):60-65. PubMed ID: 31587986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
    Rovirosa A; Valduvieco I; Ascaso C; Herreros A; Bautista C; Romera I; Arenas M; Pahisa J; Biete A
    Clin Transl Oncol; 2013 Feb; 15(2):111-6. PubMed ID: 22855177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results.
    Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Holub K; Camarasa A; Sabater S; Oses G; García-Miguel J; Rivera Y; Arenas M
    Brachytherapy; 2017; 16(1):147-152. PubMed ID: 28029590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma.
    Rovirosa Á; Herreros A; Camacho C; Ascaso C; Sánchez J; Cortés S; Sabater S; Solà J; Torné A; Arenas M
    Brachytherapy; 2017; 16(6):1169-1174. PubMed ID: 28801116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma.
    Zhang Y; Fornes B; Gómez G; Bentoldrà I; Carmona C; Herreros A; Sabater S; Nicolás I; Li Y; Sánchez J; Biete A; Torné A; Ascaso C; Rovirosa Á
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092163
    [No Abstract]   [Full Text] [Related]  

  • 13. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules.
    Rovirosa A; Ascaso C; Arenas M; Sabater S; Herreros A; Camarasa A; Rios I; Holub K; Pahisa J; Biete A
    Radiother Oncol; 2015 Jul; 116(1):143-8. PubMed ID: 26194144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?
    Zhang Y; Ascaso C; Herreros A; Sánchez J; Del Pino M; Torné A; Li Y; Sabater S; Arenas M; Biete A; Rovirosa Á
    Clin Transl Oncol; 2020 Aug; 22(8):1295-1302. PubMed ID: 31865604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
    Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
    Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
    Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
    Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.
    Rovirosa A; Ascaso C; Sánchez-Reyes A; Herreros A; Abellana R; Pahisa J; Lejarcegui JA; Biete A
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):418-23. PubMed ID: 20800388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis.
    Autorino R; Tagliaferri L; Campitelli M; Smaniotto D; Nardangeli A; Mattiucci GC; Macchia G; Gui B; Miccò M; Mascilini F; Ferrandina G; Kovacs G; Valentini V; Gambacorta MA
    J Contemp Brachytherapy; 2018 Aug; 10(4):315-320. PubMed ID: 30237815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society.
    Harkenrider MM; Grover S; Erickson BA; Viswanathan AN; Small C; Kliethermes S; Small W
    Brachytherapy; 2016; 15(1):23-9. PubMed ID: 26620818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcome of Exclusively Radiographer-led Delivery of Postoperative Vaginal Vault Brachytherapy for Endometrial Cancer - The Addenbrooke's Experience.
    Buckley H; Bradshaw K; Gregory D; Prewett S; Tan LT
    Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):844-849. PubMed ID: 31307862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.